Drug intelligence / Profile preview

3-isobutyl-1-methylxanthine

Development stage
Unknown
Modality
Small Molecules
01

Overview

3-isobutyl-1-methylxanthine (IBMX) is a synthetic xanthine derivative widely used in research as a non-selective, non-specific inhibitor of cyclic nucleotide phosphodiesterases (PDEs), particularly those that degrade cAMP and cGMP. By inhibiting these enzymes, IBMX increases intracellular levels of cAMP and cGMP, leading to activation of downstream signaling pathways. It also acts as an antagonist at adenosine receptors. These actions make it a valuable tool in studies involving signal transduction, melanogenesis induction, oocyte maturation arrest, neuroprotection, cardiovascular function modulation, and smooth muscle relaxation. IBMX has no approved pharmaceutical indications but is extensively used in laboratory settings for mechanistic studies related to metabolism, cognition enhancement research, respiratory disease models (due to bronchodilatory effects), and sports science[1][2][5].

Other names
isobutylmethylxanthinemethylisobutylxanthine1-methyl-3-isobutylxanthineisobutyltheophyllineMIX
02

Targets

PDE (Phosphodiesterase family)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on 3-isobutyl-1-methylxanthine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-isobutyl-1-methylxanthine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call